Immune cells take on brain cancer in first human test
Disease control
Ongoing
This early-phase trial tests a new treatment for people with a rare and hard-to-treat type of lymphoma that has spread to the brain or spinal cord. The therapy uses the patient's own immune cells, modified to target two markers (CD19 and CD22) on cancer cells, and is given throug…
Phase: EARLY_PHASE1 • Sponsor: Hrain Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC